NewcelX Announces New CFO Appointment Following Merger
NewcelX Ltd. has appointed Mr. Omri Hagai as its new Chief Financial Officer, effective December 10, 2025, following the resignation of interim CFO Mr. Uri Ben Or. This change comes after the merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd. Mr. Hagai's extensive experience in public companies is expected to enhance NewcelX's financial leadership. The company currently has a market cap of $2M and an average trading volume of 180,091.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from NewcelX ( (NCEL) ) is now available.
NewcelX Ltd., a company involved in a merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd., announced the appointment of Mr. Omri Hagai as its new Chief Financial Officer, effective December 10, 2025. This appointment follows the resignation of the interim CFO, Mr. Uri Ben Or, and is not due to any disagreements within the company. Mr. Hagai brings significant experience from his previous roles in public companies across the technology and industrial sectors, which is expected to strengthen NewcelX’s financial leadership.
More about NewcelX
Average Trading Volume: 180,091
Technical Sentiment Signal: Sell
Current Market Cap: $2M
